A new clinical trial, Enlighten, is assessing a blood test designed to detect 10 different types of cancer in their very early stages.
Developed by Proteotype Diagnostics and led by the Southampton Clinical Trials Unit, the test identifies specific proteins in the blood that indicate the immune system's response to initial cancer signs.
Unlike other tests focusing on abnormal DNA, Enlighten targets protein levels, which experts believe are more effective for detecting cancer at its earliest stages.
The Modernised trial aims to recruit 1,000 patients across various solid tumour types, with 450 already participating, and is running at multiple hospital sites in the UK.
Researchers emphasise that early cancer detection, facilitated by such tests, is crucial for improving treatment options and increasing successful outcomes for patients.